


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on April 13, 2006.



Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE  
STATEMENT

Patent Application

Docket No. ARS-108

Serial No. 10/540,234

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Amanda Proudfoot, Maureen Ajuebor, Mark Swain  
Serial No. : 10/540,234  
Filed : June 21, 2005  
Conf. No. : 1629  
For : CC-Chemokine Mutants Against Liver Diseases

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:


In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicants have not submitted copies of the U.S. patents and published U.S. Patent Application cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Published International Application WO 02/30464, cited as F6 on the attached form PTO/SB/08, is written in a foreign language. WO 02/30464 is cited concurrently with Database WPI Section CH, Week 200242, Derwent Publications Ltd., XP002238282 on the International Search Report, a copy of which is attached, from corresponding International Application No. PCT/EP03/51090. Applicants have also included published U.S. Application No. 2005/0053603, cited as U3, on attached form PTO/SB/08, which is believed to be an English language equivalent of WO 02/30464. Applicants note that although the specification of the WO 02/30464 application is written in a foreign language, an English language Abstract is provided therewith. Applicants respectfully request that these references be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/fes/sl

Attachments: Form PTO/SB/08; copies of references cited therein; copy of International Search Report.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/540,234
				Filing Date	June 21, 2005
				First Named Inventor	Amanda Proudfoot
				Art Unit	Unknown
				Examiner Name	unknown
Sheet	1	of	2	Attorney Docket Number	ARS-108

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (if known)			
	U1	US- 5,739,103	04-14-1998	Rollins <i>et al.</i>	All
	U2	US- 5,965,697	10-12-1999	Czaplewski <i>et al.</i>	All
	U3	US-2005/0053603 A1	03-10-2005	Egashira <i>et al.</i>	All
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1	EP 1 325 751 A1	07-09-2003	Daiichi Pharm. Co. Ltd.	All	
	F2	WO 03/051921 A1	06-26-2003	Applied Research Systems, ARS Holding N.V.	All	
	F3	WO 02/028419 A2	04-11-2002	Applied Research Systems, ARS Holding N.V.	All	
	F4	WO 98/013495 A1	04-02-1998	British Biotech Pharm., <i>et al.</i>	All	
	F5	WO 96/38559 A1	12-05-1996	Dana Farber Cancer Inst. Inc.	All	
	F6	WO 02/30464	04-18-2002	Daiichi Seiyaku Co.	All	X
	F7					
	F8					
	F9					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/540,234
				Filing Date	June 21, 2005
				First Named Inventor	Amanda Proudfoot
				Group Art Unit	Unknown
				Examiner Name	unknown
Sheet	2	of	2	Attorney Docket Number	ARS-108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	Database WPI, Section Ch, Week 200242, ACCESSION NO. 2002-394437, XP002238282, April 18, 2002.	
	R2	LAURENCE, J. S. <i>et al.</i> "Importance of basic residues and quaternary structure in the function of MIP-1beta: CCR5 binding and cell surface sugar interactions" <i>Biochemistry</i> , April 24, 2001, pp. 4990-4999, Vol. 40, No. 16.	
	R3	KOOPMANN, W. <i>et al.</i> "Identification of a glycosaminoglycan-binding site in chemokine macrophage inflammatory protein-1-alpha" <i>Journal of Biological Chemistry</i> , April 11, 1997, pp. 10103-10109, Vol. 272, No. 15.	
	R4	FISHER, N.C. <i>et al.</i> "Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1alpha in alcoholic liver disease" <i>Gut</i> , 1999, pp. 416-420, Vol. 45, No. 3.	
	R5	MIYAGUCHI, S. <i>et al.</i> "Elevated plasma RANTES in primary biliary cirrhosis patients" <i>Hepatology Research</i> , 1997, pp. 156-163, Vol. 8, No. 3.	
	R6	AJUEBOR, M. <i>et al.</i> "Novel protective effects of the CC chemokine CCL2/MCP-1 in concanavalin A-induced acute hepatitis" <i>Gastroenterology</i> , April 2002, pg. A-637, Vol. 122, No. 4, Suppl. 1, abstract only.	
	R7	AJUEBOR, M. <i>et al.</i> "The coordinated action of CC chemokines and their receptors may orchestrate hepatic inflammation during chronic experimental cholangitis" <i>Gastroenterology</i> , July 2002, pg. 57, Vol. 123, No. 1, Suppl., abstract only.	
	R8	AJUEBOR, M. <i>et al.</i> "CCL3/MIP-1 alpha, a crucial chemokine in the pathogenesis of T-cell mediated hepatitis in mice" <i>Biosis</i> , March 2003, pp. 1-2, XP002263040.	
	R9	PROUDFOOT, A. E. I. <i>et al.</i> "Strategies for chemokine antagonists as therapeutics" <i>Seminars in Immunology</i> , 2003, pp. 57-65, Vol. 15, No. 1.	
	R10		
	R11		
	R12		
	R13		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.